UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 451

Sortiert nach

Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human

Molecular pharmaceutics, 2020-11, Vol.17 (11), p.4114-4124

2020

Link zum Volltext

Verfügbarkeit prüfen

Progress in brain penetration evaluation in drug discovery and development

The Journal of pharmacology and experimental therapeutics, 2008-05, Vol.325 (2), p.349

2008

Link zum Volltext

Verfügbarkeit prüfen

Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells

Antimicrobial agents and chemotherapy, 2021-08, Vol.65 (9), p.e0060221-e0060221

2021

Link zum Volltext

Verfügbarkeit prüfen

Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine

Drug metabolism and disposition, 2020-07, Vol.48 (7), p.528-536

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Journal of clinical pharmacology, 2009-05, Vol.49 (5), p.513-533

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models

The Journal of pharmacology and experimental therapeutics, 2012-03, Vol.340 (3), p.549

2012

Link zum Volltext

Verfügbarkeit prüfen

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

Xenobiotica, 2015-01, Vol.45 (1), p.45-59

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans

Drug metabolism and disposition, 2014-05, Vol.42 (5), p.918

2014

Link zum Volltext

Verfügbarkeit prüfen

Development of a computational approach to predict blood-brain barrier permeability

Drug metabolism and disposition, 2004-01, Vol.32 (1), p.132

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models

Drug metabolism and disposition, 2008-07, Vol.36 (7), p.1267

2008

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration

Drug metabolism and disposition, 2006-09, Vol.34 (9), p.1443

2006

Link zum Volltext

Verfügbarkeit prüfen

Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding

The Journal of pharmacology and experimental therapeutics, 2005-06, Vol.313 (3), p.1254

2005

Link zum Volltext

Verfügbarkeit prüfen

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model

Drug metabolism and disposition, 2015-10, Vol.43 (10), p.1417-1429

2015

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Seasonal Pharmacokinetic Variability in Woodchucks

Drug metabolism and disposition, 2020-11, Vol.48 (11), p.1199-1209

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species

Drug metabolism and disposition, 2022-03, Vol.50 (3), p.197-203

2022

Link zum Volltext

Verfügbarkeit prüfen

18O‑Enabled High-Throughput Acyl Glucuronide Stability Assay

Chemical research in toxicology, 2022-08, Vol.35 (8), p.1400-1409

2022

Link zum Volltext

Verfügbarkeit prüfen

Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

Xenobiotica, 2022-11, Vol.52 (9-11), p.973-985

2022

Link zum Volltext

Verfügbarkeit prüfen

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

Molecular pharmaceutics, 2023-12, Vol.20 (12), p.6213-6225

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development

Drug metabolism and disposition, 2018-03, Vol.46 (3), p.237-247

2018

Link zum Volltext

Verfügbarkeit prüfen

Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs

Drug metabolism and disposition, 2023-10, Vol.51 (10), p.1362

2023

Link zum Volltext

Verfügbarkeit prüfen

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection

Antiviral research, 2022-07, Vol.203, p.105329-105329, Article 105329

2022

Link zum Volltext

Verfügbarkeit prüfen

Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors

Drug metabolism and disposition, 2013-06, Vol.41 (6), p.1285

2013

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Kinetic Characterization of Axitinib Metabolism

Drug metabolism and disposition, 2016-01, Vol.44 (1), p.102-114

2016

Link zum Volltext

Verfügbarkeit prüfen

In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions

Drug metabolism and disposition, 2013-08, Vol.41 (8), p.1575

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 451

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(385)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human

Progress in brain penetration evaluation in drug discovery and development

Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells

Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans

Development of a computational approach to predict blood-brain barrier permeability

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration

Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding

Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model

Characterization of Seasonal Pharmacokinetic Variability in Woodchucks

Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species

18O‑Enabled High-Throughput Acyl Glucuronide Stability Assay

Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development

Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs

Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection

Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors

In Vitro Kinetic Characterization of Axitinib Metabolism

In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions

Suchergebnisse filtern